This article examines why precision delivery has become the defining factor in cell and gene therapy success, explores how accuracy in location, distribution and dose can be engineered and demonstrated, and shows how a minimum viable product approach to delivery device development can help translate CGTs into safe, scalable clinical outcomes.
Delivering therapeutics into the brain remains one of the greatest challenges in tackling neurodegenerative disease. Modern drug modalities demand delivery systems engineered with precision, safety, and modality-specific requirements in mind.
Two-component injectables promise more stable, effective treatments but create new hurdles in reconstitution and delivery. From lyophilised powders to dual-chamber systems, this article explores how device innovation is making complex therapies simpler, safer, and more accessible beyond the clinic.
Our work with Credence MedSystems won a 2025 Red Dot Design Concept Award – but more importantly, it could change the lives of countless people who need to self-administer two drugs in one injection at home. Read more on the three insightsbehind project success.
Discover the future of parenteral drug delivery through expert interviews and real-world insights. Explore innovative strategies and design approaches driving improvements in usability, patient experience, and treatment outcomes.
This article, authored by Steve Augustyn, featuring insights from Krai Chatamra, VP of Clinical Development at Intrance Medical Systems, explores the necessity of advanced therapies that provide consistent symptom control to improve patient outcomes and enable a more independent lifestyle.
Fran Pencliffe of Cambridge Design Partnership explores the benefits of platform devices for parenteral delivery and outlines the challenges, risks and best practices when bringing a combination product to market in this way.
The pharma industry’s move towards larger volumes of subcutaneous (SC) therapeutics and home-based care is increasing the demand for self-administration devices. We recently partnered with KORU to explore innovations in infusion pump technology aimed at enhancing patient comfort and convenience
We recently partnered with Re-Vana Therapeutics, pioneers in sustained-release technologies for a range of eye diseases. In this article, Re-Vana's Patrick H. O'Ruane, along with Cambridge Design Partnership's Dariusz Zak and Fran Pencliffe, discuss how advancing sustained-release therapies can help ease the burden of acute treatments.
We recently collaborated with Lent Innovations to explore critical issues in pediatric epinephrine injectors. Our latest article features insights from Dr. Annie Lent and our Deputy Head of Drug Delivery, Steve Augustyn.
Insights from Industry Experts on Training for Patient Technique, the Value of Connected Devices, and the Shift to Low GWP pMDIs.
Discover the exciting possibilities on the horizon for inhalation device design. Explore recent advancements and innovative strategies crucial for developing significant new treatments.